Jasper Twilt

Mr. Jasper Twilt

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
JTJasper Twilt
Jasper Twilt
KLKicky G. van Leeuwen
Kicky G. van Leeuwen
HHHenkjan J. Huisman
Henkjan J. Huisman
JFJurgen Fütterer
Jurgen Fütterer
MRMaarten de Rooij
Maarten de Rooij
Due to the upfront role of magnetic resonance imaging (MRI) for prostate cancer (PCa) diagnosis, a multitude of artificial intelligence (AI) applications have been suggested to aid in the diagnosis and detection of PCa. In this review, we provide an overview of the current field, including studies between 2018 and February 2021, describing AI algorithms for (1) lesion classification and (2) lesion detection for PCa. Our evaluation of 59 included studies showed that most research has been conducted for the task of PCa lesion classification (66%) followed by PCa lesion detection (34%). Studies showed large heterogeneity in cohort sizes, ranging between 18 to 499 patients (median = 162) combined with different approaches for performance validation. Furthermore, 85% of the studies reported on the stand-alone diagnostic accuracy, whereas 15% demonstrated the impact of AI on diagnostic thinking efficacy, indicating limited proof for the clinical utility of PCa AI applications. In order to introduce AI within the clinical workflow of PCa assessment, robustness and generalizability of AI applications need to be further validated utilizing external validation and clinical workflow experiments.

22 October 2024 in European Urology
Verified
Journal Article
Open access
JTJasper Twilt
Jasper Twilt
ASAnindo Saha
Anindo Saha
JBJoeran S. Bosma
Joeran S. Bosma
BGBram van Ginneken
Bram van Ginneken
ABAnders Bjartell
Anders Bjartell
YLYoung Joon Lee
Young Joon Lee
Biparametric magnetic resonance imaging (bpMRI), excluding dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI), is a potential replacement for multiparametric MRI (mpMRI) in diagnosing clinically significant prostate cancer (csPCa). An extensive international multireader multicase observer study was conducted to assess the noninferiority of bpMRI to mpMRI in csPCa diagnosis. An observer study was conducted with 400 mpMRI examinations from four European centers, excluding examinations with prior prostate treatment or csPCa (Gleason grade [GG] ≥2) findings. Readers assessed bpMRI and mpMRI sequentially, assigning lesion-specific Prostate Imaging Reporting and Data System (PI-RADS) scores (3-5) and a patient-level suspicion score (0-100). The noninferiority of patient-level bpMRI versus mpMRI csPCa diagnosis was evaluated using the area under the receiver operating curve (AUROC) alongside the sensitivity and specificity at PI-RADS ≥3 with a 5% margin. The secondary outcomes included insignificant prostate cancer (GG1) diagnosis, diagnostic evaluations at alternative risk thresholds, decision curve analyses (DCAs), and subgroup analyses considering reader expertise. Histopathology and ≥3 yr of follow-up were used for the reference standard. Sixty-two readers (45 centers and 20 countries) participated. The prevalence of csPCa was 33% (133/400); bpMRI and mpMRI showed similar AUROC values of 0.853 (95% confidence interval [CI], 0.819-0.887) and 0.859 (95% CI, 0.826-0.893), respectively, with a noninferior difference of -0.6% (95% CI, -1.2% to 0.1%, p < 0.001). At PI-RADS ≥3, bpMRI and mpMRI had sensitivities of 88.6% (95% CI, 84.8-92.3%) and 89.4% (95% CI, 85.8-93.1%), respectively, with a noninferior difference of -0.9% (95% CI, -1.7% to 0.0%, p < 0.001), and specificities of 58.6% (95% CI, 52.3-63.1%) and 57.7% (95% CI, 52.3-63.1%), respectively, with a noninferior difference of 0.9% (95% CI, 0.0-1.8%, p < 0.001). At alternative risk thresholds, mpMRI increased sensitivity at the expense of reduced specificity. DCA demonstrated the highest net benefit for an mpMRI pathway in cancer-averse scenarios, whereas a bpMRI pathway showed greater benefit for biopsy-averse scenarios. A subgroup analysis indicated limited additional benefit of DCE MRI for nonexperts. Limitations included that biopsies were conducted based on mpMRI imaging, and reading was performed in a sequential order. It has been found that bpMRI is noninferior to mpMRI in csPCa diagnosis at AUROC, along with the sensitivity and specificity at PI-RADS ≥3, showing its value in individuals without prior csPCa findings and prostate treatment. Additional randomized prospective studies are required to investigate the generalizability of outcomes.

2 June 2025 in JAMA Network Open
Verified
Journal Article
Open access
JTJasper Twilt
Jasper Twilt
ASAnindo Saha
Anindo Saha
JBJoeran S Bosma
Joeran S Bosma
APAnwar R Padhani
Anwar R Padhani
DBDavid Bonekamp
David Bonekamp
PCPI-CAI Consortium
PI-CAI Consortium
Importance: Artificial intelligence (AI) assistance in magnetic resonance imaging (MRI) assessment for prostate cancer shows promise for improving diagnostic accuracy but lacks large-scale observational evidence.Objective: To evaluate whether use of AI-assisted assessment for diagnosing clinically significant prostate cancer (csPCa) on MRI is superior to unassisted readings.Design, Setting, and Participants: This diagnostic study was conducted between March and July 2024 to compare unassisted and AI-assisted diagnostic performance using the AI system developed within the international Prostate Imaging-Cancer AI (PI-CAI) Consortium. The study involved 61 readers (34 experts and 27 nonexperts) from 53 centers across 17 countries. Readers assessed prostate magnetic resonance images both with and without AI assistance, providing Prostate Imaging Reporting and Data System (PI-RADS) annotations from 3 to 5 (higher PI-RADS indicated a higher likelihood of csPCa) and patient-level suspicion scores ranging from 0 to 100 (higher scores indicated a greater likelihood of harboring csPCa). Biparametric prostate MRI examinations were included for 780 men from the PI-CAI study who were included in the newly-conducted observer study. All men within the PI-CAI study had suspicion of harboring prostate cancer, sufficient diagnostic image quality, and no prior clinically significant cancer findings. Disease presence was defined by histopathology, and absence was determined by 3 or more years of follow-up. The AI system was recalibrated using 420 Dutch examinations to generate lesion-detection maps, with AI scores ranging from 1 to 10, in which 10 indicates the highest likelihood of csPCa. The remaining 360 examinations, originating from 3 Dutch centers and 1 Norwegian center, were included in the observer study.Main Outcomes and Measures: The primary outcome was diagnosis of csPCa, evaluated using the area under the receiver operating characteristic curve and sensitivity and specificity at a PI-RADS threshold of 3 or more. The secondary outcomes included analysis at alternate operating points and reader expertise.Results: Among the 360 examinations of 360 men (median age, 65 years [IQR, 62-70 years]) who were included for testing, 122 (34%) harbored csPCa. AI assistance was associated with significantly improved performance, achieving a 3.3% increase in the area under the receiver operating characteristic curve (95% CI, 1.8%-4.9%; P < .001), from 0.882 (95% CI, 0.854-0.910) in unassisted assessments to 0.916 (95% CI, 0.893-0.938) with AI assistance. Sensitivity improved by 2.5% (95% CI, 1.1%-3.9%; P < .001), from 94.3% (95% CI, 91.9%-96.7%) to 96.8% (95% CI, 95.2%-98.5%), and specificity increased by 3.4% (95% CI, 0.8%-6.0%; P = .01), from 46.7% (95% CI, 39.4%-54.0%) to 50.1% (95% CI, 42.5%-57.7%), at a PI-RADS score of 3 or more. Secondary analyses demonstrated similar performance improvements across alternate operating points and a greater benefit of AI assistance for nonexpert readers.Conclusions and Relevance: The findings of this diagnostic study of patients suspected of harboring prostate cancer suggest that AI assistance was associated with improved radiologic diagnosis of clinically significant disease. Further research is required to investigate the generalization of outcomes and effects on workflow improvement within prospective settings.

21 November 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
JBJoeran S. Bosma
Joeran S. Bosma
LBLuc Builtjes
Luc Builtjes
ASAnindo Saha
Anindo Saha
JTJasper Twilt
Jasper Twilt
Manolis TsiknakisManolis Tsiknakis
Manolis Tsiknakis
HHHenkjan J. Huisman
Henkjan J. Huisman
Deep learning can mitigate the global radiologist shortage but its development requires large-scale annotated datasets. This study introduces SCALE (Scalable Clinical Annotation with Location Evidence), a fully automated method for generating voxel-level annotations. It uses location priors that are automatically extracted from medical reports, tracked biopsy coordinates, or provided anatomical sectors. We annotated a large-scale dataset comprising 17 896 cases from 16 562 patients across 24 hospitals in 10 countries and 2 continents, using both SCALE and a count-based weakly semisupervised learning (CWSSL) method. An optimized algorithm was developed and trained on these datasets. Evaluation with 1561 cases from 1561 patients across 19 hospitals in 3 countries and 1 continent showed the superiority of the model trained on the dataset with SCALE annotations, achieving a case-level area under the receiver operating characteristic curve of 0.856. This is +0.012 compared to supervised learning (p=0.02), +0.007 compared to training with CWSSL (p=0.12), and +0.006 compared to the Prostate Imaging: Cancer AI (PI-CAI) Ensemble AI System. These results demonstrate that automated, location-guided annotation enables scalable development of AI for clinically significant prostate cancer detection on MRI, surpassing previous methods, and paving the way for broader clinical deployment.

5 October 2024
Verified
Book Chapter
Closed access
PDF file
AHAlessa Hering
Alessa Hering
SBSarah de Boer
Sarah de Boer
ASAnindo Saha
Anindo Saha
JTJasper Twilt
Jasper Twilt
MHMattias P. Heinrich
Mattias P. Heinrich
JBJoeran S. Bosma
Joeran S. Bosma

1 May 2026 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
JTJasper Twilt
Jasper Twilt
ASAnindo Saha
Anindo Saha
JBJoeran S Bosma
Joeran S Bosma
GGGianluca Giannarini
Gianluca Giannarini
APAnwar R Padhani
Anwar R Padhani
PCPI-CAI Consortium
PI-CAI Consortium
A simulated artificial intelligence–driven triaging workflow for clinically significant prostate cancer diagnosis at MRI triaged 49% of examinations, improving specificity while maintaining radiologist-level sensitivity.